肝细胞癌(hepatocellular carcinoma,HCC)是我国最常见的恶性肿瘤之一,死亡率在恶性肿瘤中排列第3位,仅次于胃癌及食道癌,严重威胁着人们的健康[1]。目前HCC的治疗仍是以手术为主实施综合治疗,但部分病例就诊时已失去手术时机,且术后复发率高,5年生存率低。近年来,新生血管在肿 Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in our country. The mortality rate ranks the third in malignant tumors, second only to gastric cancer and esophageal cancer, which is a serious threat to people’s health [1]. The current treatment of HCC is still based on the implementation of comprehensive surgical treatment, but some cases have lost the opportunity to seek treatment, and postoperative recurrence rate, 5-year survival rate is low. In recent years, neovascularization is swollen